Electronic Instruments Maker AMETEK Buys Paragon Medical For $1.9B Cash; Raises FY23 EPS Outlook

AMETEK Inc AME reported Q3 FY23 revenue growth of 5% Y/Y to $1.62 billion, missing the consensus of $1.66 billion. 

Electronic Instruments Group (EIG) segment sales grew 8% Y/Y to $1.14 billion on strong organic sales growth and contributions from recent acquisitions.

EIG's operating income rose 23% Y/Y to $335.2 million, with margins of 29.5% (+360 basis points Y/Y).

Electromechanical Group (EMG) segment sales fell 2% Y/Y to $486.7 million, and operating income stood at $127.5 million (margins at 26.2%).

Operating income increased 14% Y/Y to $438.1 million, with margins expansion of 220 basis points Y/Y to 27.0%. 

Adjusted EPS rose 13% Y/Y to $1.64, beating the consensus of $1.58.

Operating cash flow in the quarter stood at $473 million, up 45% Y/Y. As of September 30, cash and cash equivalents stood at $841.9 million.

Outlook: AMETEK raised the adjusted EPS outlook to $6.31-$6.33 (from $6.18-$6.26) vs. consensus of $6.25 for FY23.

AMETEK continues to expect FY23 sales to be up mid-to-high single digits.

For Q4, AMETEK sees sales to be up mid-single digits Y/Y and adjusted EPS of $1.61-$1.63 vs. consensus of $1.61.

In a separate development, AMETEK acquired Amplifier Research Corp. for an undisclosed amount and inked a deal to acquire Paragon Medical for about $1.9 billion.

Price Action: AME shares are trading higher by 0.17% at $140.36 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsEquitiesLarge CapM&ANewsGuidanceMarketsBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!